Sad news for ResTORbio, whose lead drug candidate, a rapamycin-like mTOR inhibitor, failed

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.